BFRG vs RXRX vs ABSI vs AIXI vs INVA

For growth investors, Recursion Pharmaceuticals, Inc.

(RXRX) is the stronger pick with 26. 9% revenue growth year-over-year, versus -38. 2% for Absci Corporation (ABSI). Innoviva, Inc. (INVA) offers the better valuation at 6. 9x trailing P/E (11. 9x forward), making it the more compelling value choice. Analysts rate Absci Corporation (ABSI) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Innoviva, Inc.

(INVA) delivered a total return of +94. 4%, compared to -98. 6% for Xiao-I Corporation (AIXI). Over 10 years, the gap is even starker: INVA returned +94. 9% versus AIXI's -98. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Innoviva, Inc.

(INVA) is the lower-risk stock at 0. 13β versus Recursion Pharmaceuticals, Inc. 's 3. 18β — meaning RXRX is approximately 2419% more volatile than INVA relative to the S&P 500. On balance sheet safety, Absci Corporation (ABSI) carries a lower debt/equity ratio of 3% versus 23% for Innoviva, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Recursion Pharmaceuticals, Inc.

(RXRX) is pulling ahead at 26. 9% versus -38. 2% for Absci Corporation (ABSI). On earnings-per-share growth, the picture is similar: Innoviva, Inc. grew EPS 816. 7% year-over-year, compared to 10. 6% for Absci Corporation. Over a 3-year CAGR, BFRG leads at 225. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Innoviva, Inc.

(INVA) is the more profitable company, earning 63. 8% net margin versus -55. 7% for Bullfrog AI Holdings, Inc. Common Stock — meaning it keeps 63. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INVA leads at 38. 5% versus -56. 5% for BFRG. At the gross margin level — before operating expenses — INVA leads at 72. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for RXRX: 236.

4% to $11. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Innoviva, Inc.

(INVA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 13)). Bullfrog AI Holdings, Inc. Common Stock (BFRG) carries a higher beta of 3. 07 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (INVA: +94. 9%, BFRG: -90. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (BFRG (Healthcare) and RXRX (Healthcare) and ABSI (Healthcare) and AIXI (Technology) and INVA (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: BFRG is a small-cap quality compounder stock; RXRX is a small-cap high-growth stock; ABSI is a small-cap quality compounder stock; AIXI is a small-cap high-growth stock; INVA is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.